Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ying-Ka Lau"'
Autor:
Ying Ka Lau, Jennifer L. West
Publikováno v:
Molecular Therapy. 13:S138-S139
Angiogenesis is important in tumor biology, ischemic diseases, wound healing and many other areas. In our study, we studied the effect of overexpression of vascular endothelial growth factor (VEGF) in mouse embryonic stem cells (10T1/2 cells)through
Autor:
Ramona Jayasena, Dawn L. Hershman, Kevin Kalinsky, Ying-Ka Lau, Katherine D. Crew, Ramon Parsons, Julia Forman, Matthew A. Maurer
Publikováno v:
Cancer Research. 73:28-28
A large subset of triple negative breast cancers (TNBC) are driven in part by a combination of activated growth factor signaling and downstream constitutive activation of the PI3K pathway. We have hypothesized that targeting the EGFR, PTEN and DNA da
Publikováno v:
Annals of Biomedical Engineering; Aug2006, Vol. 34 Issue 8, p1239-1246, 8p
Autor:
Qing-Bai She, Gruvberger-Saal, Sofia, Maurer, Matthew, Yilun Chen, Jumppanen, Mervi, Su, Tao, Dendy, Meaghan, Ying-Ka Lau, Memeo, Lorenzo, Horlings, Hugo, Vijver, Marc Van De, Isola, Jorma, Hanina Hibshoosh, Rosen, Neal, Parsons, Ramon, Saal, Lao
Chronic treatment with gefitinib and PWT-458, alone or in combination, does not cause eight loss in mice. Mice bearing MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg five imes/week), gefitinib (150 mg/kg five times/week), combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4144eb2b3c90ae5e76d737651b5c1317
Autor:
Qing-Bai She, Gruvberger-Saal, Sofia, Maurer, Matthew, Yilun Chen, Jumppanen, Mervi, Su, Tao, Dendy, Meaghan, Ying-Ka Lau, Memeo, Lorenzo, Horlings, Hugo, Vijver, Marc Van De, Isola, Jorma, Hanina Hibshoosh, Rosen, Neal, Parsons, Ramon, Saal, Lao
HCC70 (A) or SUM149 (B) cells were treated with single-agent gefitinib (left) or combination treatment with 5 ÎźM LY294002 plus gefitinib at the concentrations indicated and cell proliferation measured over 4 days. (PDF 217 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9bba2adac879343501bbb95056c2dc3
Autor:
Qing-Bai She, Gruvberger-Saal, Sofia, Maurer, Matthew, Yilun Chen, Jumppanen, Mervi, Su, Tao, Dendy, Meaghan, Ying-Ka Lau, Memeo, Lorenzo, Horlings, Hugo, Vijver, Marc Van De, Isola, Jorma, Hanina Hibshoosh, Rosen, Neal, Parsons, Ramon, Saal, Lao
Chronic treatment with gefitinib and PWT-458, alone or in combination, does not cause eight loss in mice. Mice bearing MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg five imes/week), gefitinib (150 mg/kg five times/week), combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7117caa26733d1dbd915f80ede59e444
Autor:
Qing-Bai She, Gruvberger-Saal, Sofia, Maurer, Matthew, Yilun Chen, Jumppanen, Mervi, Su, Tao, Dendy, Meaghan, Ying-Ka Lau, Memeo, Lorenzo, Horlings, Hugo, Vijver, Marc Van De, Isola, Jorma, Hanina Hibshoosh, Rosen, Neal, Parsons, Ramon, Saal, Lao
HCC70 (A) or SUM149 (B) cells were treated with single-agent gefitinib (left) or combination treatment with 5 ÎźM LY294002 plus gefitinib at the concentrations indicated and cell proliferation measured over 4 days. (PDF 217 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d012188a0636f73f5ac088f6bf742f84